$ABEO
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Healthcare
Sector
Biotechnology
Industry
Vishwas Seshadri
CEO
136
Employees
$5.16
Current Price
$277.46M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 4 | $208,430.60 | 40,428 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 4 | $208,430.60 | 40,428 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 5 | 5 | $296,396.60 | 55,428 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 5 | 6 | $306,047.94 | 56,906 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Sep 29, 2026 | Seshadri Vishwas Director | Sale | 19,608 | $5.16 | $101,091.00 | View Details |
| Sep 29, 2026 | Vazzano Joseph Walter Chief Financial Officer | Sale | 9,191 | $5.16 | $47,385.12 | View Details |
| Sep 29, 2026 | O'Malley Brendan M. SVP, Chief Legal Officer | Sale | 6,727 | $5.16 | $34,681.72 | View Details |
| Sep 29, 2026 | Vasanthavada Madhav Chief Commercial Officer | Sale | 4,902 | $5.16 | $25,272.75 | View Details |
| Sep 1, 2026 | Alvino Mark Director | Sale | 15,000 | $5.86 | $87,966.00 | View Details |
| Jul 21, 2026 | Vazzano Joseph Walter Chief Financial Officer | Sale | 1,478 | $6.53 | $9,651.34 | View Details |
| Jul 9, 2026 | Vazzano Joseph Walter Chief Financial Officer | Sale | 24,880 | $6.96 | $173,256.86 | View Details |
| Jul 9, 2026 | Seshadri Vishwas Director | Sale | 67,971 | $6.96 | $473,329.65 | View Details |
| Jul 9, 2026 | O'Malley Brendan M. SVP, Chief Legal Officer | Sale | 12,050 | $6.96 | $83,912.59 | View Details |
| Jul 9, 2026 | Vasanthavada Madhav Chief Commercial Officer | Sale | 12,606 | $6.96 | $87,784.40 | View Details |
29 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.